高压氧作为局部晚期口咽鳞癌放疗增敏剂:一期剂量递增研究
HBO频率从每周2次递增至5次,未观察到剂量限制性毒性,方案内分析显示5年总生存率100%、局部复发0%、远处转移11%。
要点
- HBO每日给药未出现剂量限制性毒性,2例(22%)需鼓膜置管。
- HBO与放疗平均间隔8.5分钟,231次给药中仅2次(0.5%)超过15分钟。
- 方案内分析5年总生存率100%、局部复发0%、远处转移11%。
核心结论
- 研究深入审查所获数据表明,高压氧联合放化疗在局部晚期口咽鳞癌中具有可行性。
研究设计与样本
- 患者接受调强放疗70 Gy/35次/7周,同步每周顺铂化疗。
- HBO为100%氧气、2.4 ATA、30分钟,初始每周2次,后续递增至每周3次和5次。
- 放疗在HBO开始后15分钟内进行,随访2年评估生活质量,5年以上评估复发和生存。
主要发现
- 剩余9例均为原发口咽病,其中IVA期7例、IVB期2例。
- 每日HBO未观察到剂量限制性毒性,2例(22%)需鼓膜置管。
- HBO与放疗平均间隔8.5分钟,231次给药中2次(0.5%)超过15分钟。
- 方案内分析显示临床完全缓解7例,2例挽救性颈清扫未见肿瘤即病理完全缓解。
关键数值与推荐
- 入组标准为III-IV期(M0)头颈鳞癌、预期寿命>6个月、Karnofsky体能状态评分≥70。
- 放疗剂量为70 Gy/35次/7周,同步每周顺铂。
- HBO方案为100%氧气、2.4 ATA、30分钟,频率从每周2次递增至5次。
- 放疗需在HBO开始后15分钟内进行。
临床怎么用
- 在局部晚期口咽鳞癌放化疗前即刻给予高压氧在技术上可行,但需多中心更大样本验证。
- HBO与放疗的15分钟时间窗在多数情况下可达到,需具备快速转运和放疗衔接流程。
- 鼓膜置管是常见不良事件,需耳鼻喉科评估支持。
局限性
- 仅9例口咽癌患者纳入方案内分析,代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore, in a dose-escalation study, the feasibility of hyperbaric oxygen (HBO) treatments immediately before intensity modulated radiation therapy in conjunction with cisplatinum chemotherapy for squamous cell carcinoma of the head and neck (SCCHN). METHODS AND MATERIALS: Eligible patients presented with SCCHN (stage III-IV [M0]), life expectancy >6 months, and Karnofsky performance status ≥70. Enrollees received intensity modulated radiation therapy, 70 Gy in 35 fractions over 7 weeks with weekly cisplatinum. Patients received HBO-100% oxygen, 2.4 atmospheres absolute (ATA) for 30 minutes-twice per week initially. Subsequent patients were escalated to 3 and then 5 times per week. Intensity modulated radiation therapy began within 15 minutes after HBO. Patients were followed for 2 years after RT with quality-of-life questionnaires (Performance Status Scale-Head and Neck Cancer and the Functional Assessment of Cancer Therapy-Head and Neck Cancer) and for 5+ years for local recurrence, distant metastases, disease-specific survival, and overall survival. RESULTS: Twelve subjects enrolled from 3 centers. Two withdrew during radiation therapy and 1 within 14 weeks after radiation therapy. The remaining 9 had primary oropharyngeal disease and were stage IVA (7) or IVB (2). No dose-limiting toxicities were observed with daily HBO. Two patients (22%) required pressure equalization tubes. The average time between HBO and radiation therapy was 8.5 minutes, with 2 of 231 administrations delivered beyond 15 minutes (0.5%). Per-protocol analysis showed a clinical complete response in 7 and a pathologic complete response without tumor in salvage neck dissections in 2. With minimum follow-up of 61 months, per-protocol 5-year overall survival was 100%, local recurrence 0%, and distant metastases 11%. Patient-reported outcomes for quality of life (Functional Assessment of Cancer Therapy-Head and Neck Cancer) were comparable to published results for chemoradiotherapy without HBO. CONCLUSIONS: While acknowledging the study's small size and early attrition of 3 patients, our in-depth review of the acquired data indicates the feasibility of combining HBO with chemoradiation.
引用
- Hartford AC, Davis TH, Buckey JC, et al. Hyperbaric Oxygen as Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx: A Phase 1 Dose-Escalation Study. Int J Radiat Oncol Biol Phys. 2016. PMID: 28126298. doi:10.1016/j.ijrobp.2016.10.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。